CytomX Therapeutics (CTMX) Short term Debt (2014)

CytomX Therapeutics (CTMX) reported Short term Debt of $1.4 million for Q4 2014.

CytomX Therapeutics (CTMX) Short term Debt (2014) Analysis & Trends

CytomX Therapeutics has reported Short term Debt for 1 years, with the latest figure at $1.4 million in Q4 2014.

For the quarter ending Q4 2014, Short term Debt changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2014 stood at $1.4 million (changed N/A YoY), and the FY2014 full-year result was $1.4 million, changed N/A from the prior year.
Short term Debt for Q4 2014 stood at $1.4 million.
The five-year high for Short term Debt was $1.4 million in Q4 2014, with the low at $1.4 million in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	CytomX Therapeutics	520.30 Mn	173.59 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2014	1.42 Mn